540 related articles for article (PubMed ID: 22810507)
21. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
Schoch C; Haferlach T; Bursch S; Gerstner D; Schnittger S; Dugas M; Kern W; Löffler H; Hiddemann W
Genes Chromosomes Cancer; 2002 Sep; 35(1):20-9. PubMed ID: 12203786
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251.
Luan S; Sun L; Huang F
Arch Med Res; 2010 Feb; 41(2):67-74. PubMed ID: 20470934
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.
Raver-Shapira N; Marciano E; Meiri E; Spector Y; Rosenfeld N; Moskovits N; Bentwich Z; Oren M
Mol Cell; 2007 Jun; 26(5):731-43. PubMed ID: 17540598
[TBL] [Abstract][Full Text] [Related]
24. MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma.
Lin RJ; Xiao DW; Liao LD; Chen T; Xie ZF; Huang WZ; Wang WS; Jiang TF; Wu BL; Li EM; Xu LY
J Surg Oncol; 2012 Feb; 105(2):175-82. PubMed ID: 21882196
[TBL] [Abstract][Full Text] [Related]
25. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
[TBL] [Abstract][Full Text] [Related]
26. Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.
Liu L; Chen R; Zhang Y; Fan W; Xiao F; Yan X
Diagn Pathol; 2015 Jul; 10():109. PubMed ID: 26185105
[TBL] [Abstract][Full Text] [Related]
27. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
28. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215.
Georges SA; Biery MC; Kim SY; Schelter JM; Guo J; Chang AN; Jackson AL; Carleton MO; Linsley PS; Cleary MA; Chau BN
Cancer Res; 2008 Dec; 68(24):10105-12. PubMed ID: 19074876
[TBL] [Abstract][Full Text] [Related]
29. Restoration of miR-34a in p53 deficient cells unexpectedly promotes the cell survival by increasing NFκB activity.
Tan J; Fan L; Mao JJ; Chen B; Zheng L; Zhang T; Li T; Duan J; Duan Y; Jin Z; Kuang W
J Cell Biochem; 2012 Sep; 113(9):2903-8. PubMed ID: 22531959
[TBL] [Abstract][Full Text] [Related]
30. Identification of key microRNAs associated with diffuse large B-cell lymphoma by analyzing serum microRNA expressions.
Meng Y; Quan L; Liu A
Gene; 2018 Feb; 642():205-211. PubMed ID: 29128636
[TBL] [Abstract][Full Text] [Related]
31. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.
Wang X; Li J; Dong K; Lin F; Long M; Ouyang Y; Wei J; Chen X; Weng Y; He T; Zhang H
Cell Signal; 2015 Mar; 27(3):443-52. PubMed ID: 25499621
[TBL] [Abstract][Full Text] [Related]
32. Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia.
Chen XX; Lin J; Qian J; Qian W; Yang J; Ma JC; Deng ZQ; Xie D; An C; Tang CY; Qian Z
Clin Biochem; 2014 Jan; 47(1-2):63-6. PubMed ID: 24135052
[TBL] [Abstract][Full Text] [Related]
33. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
34. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
[TBL] [Abstract][Full Text] [Related]
35. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
[TBL] [Abstract][Full Text] [Related]
37. The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy.
Rybka J; Butrym A; Wróbel T; Jaźwiec B; Stefanko E; Dobrzyńska O; Poręba R; Kuliczkowski K
Leuk Res; 2015 Mar; 39(3):318-22. PubMed ID: 25624047
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of microRNA-145 down-regulation in adult T-cell leukemia/lymphoma.
Xia H; Yamada S; Aoyama M; Sato F; Masaki A; Ge Y; Ri M; Ishida T; Ueda R; Utsunomiya A; Asai K; Inagaki H
Hum Pathol; 2014 Jun; 45(6):1192-8. PubMed ID: 24745613
[TBL] [Abstract][Full Text] [Related]
39. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.
Wang X; Dong K; Gao P; Long M; Lin F; Weng Y; Ouyang Y; Ren J; Zhang H
Cancer Biother Radiopharm; 2013 Feb; 28(1):45-50. PubMed ID: 23036084
[TBL] [Abstract][Full Text] [Related]
40. Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells.
Dalgard CL; Gonzalez M; deNiro JE; O'Brien JM
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4542-51. PubMed ID: 19443717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
